双HER2阻断下联合或不联合蒽环类新辅助化疗治疗HER2阳性乳腺癌(TRAIN-2):多中心、开放标签、随机、3期试验
TRAIN-2研究在荷兰37家医院纳入438例II-III期HER2阳性早期乳腺癌患者,随机比较蒽环类方案与非蒽环类卡铂-紫杉醇方案联合曲妥珠单抗和帕妥珠单抗。蒽环组病理完全缓解率67%(95%CI 60-73),非蒽环组68%(61-74),p=0.95;蒽环组3级及以上发热性中性粒细胞减少更常见(10% vs 1%,p<0.0001)。作者认为在双HER2阻断下省略蒽环类可能是首选方法,需长期随访确认。
要点
- 蒽环组病理完全缓解141/212(67%,95%CI 60-73),非蒽环组140/206(68%,61-74),p=0.95。
- 蒽环组3级及以上发热性中性粒细胞减少23/220(10%)vs 非蒽环组3/218(1%),p<0.0001。
- 作者认为双HER2阻断下省略蒽环类可能是首选方法,需长期随访确认。
核心结论
- 鉴于两组病理完全缓解率均较高且蒽环组发热性中性粒细胞减少更常见,作者认为在早期HER2阳性乳腺癌双HER2阻断下省略蒽环类可能是首选方法。
- 作者指出需要长期随访以确认这些结果。
研究设计与样本
- TRAIN-2为开放标签、随机、对照、3期试验,在荷兰37家医院开展。
- 纳入18岁及以上、既往未治疗、组织学确诊的II-III期HER2阳性乳腺癌患者。
- 采用中央随机化软件按1:1比例分组,以最小化法(无随机成分)按肿瘤分期、淋巴结分期、雌激素受体状态和年龄分层。
- 蒽环组接受5-氟尿嘧啶(500 mg/m2)、表柔比星(90 mg/m2)和环磷酰胺(500 mg/m2)每3周共3周期,随后紫杉醇(80 mg/m2,第1天和第8天)和卡铂(AUC 6 mg/mL per min第1天,或按医院偏好可选AUC 3 mg/mL per min第1天和第8天)每3周共6周期;非蒽环组接受9周期紫杉醇和卡铂,剂量和 schedule 与蒽环组相同。
- 两组均在所有化疗周期同时接受曲妥珠单抗(6 mg/kg,负荷剂量8 mg/kg)和帕妥珠单抗(420 mg,负荷剂量840 mg)。
主要发现
- 2013年12月9日至2016年1月14日共纳入438例患者并随机分至两组(每组219例),其中418例可评估主要终点(蒽环组212例,非蒽环组206例)。
- 所有患者中位随访19个月(IQR 16-23个月)。
- 蒽环组141/212例(67%,95%CI 60-73)达到病理完全缓解,非蒽环组140/206例(68%,61-74),p=0.95。
- 安全性分析中蒽环组220例、非蒽环组218例;严重不良事件蒽环组61/220例(28%),非蒽环组49/218例(22%)。
- 任何原因的常见不良事件:3级及以上中性粒细胞减少蒽环组131/220例(60%)vs 非蒽环组118/218例(54%);3级及以上腹泻26/220例(12%)vs 37/218例(18%);2级及以上周围神经病变66/220例(30%)vs 68/218例(31%),组间无实质性差异。
关键数值与推荐
- 主要终点为意向治疗人群中乳腺和腋窝病理完全缓解(ypT0/is ypN0)的比例。
- 蒽环组病理完全缓解141/212例(67%,95%CI 60-73),非蒽环组140/206例(68%,61-74),p=0.95。
- 3级及以上发热性中性粒细胞减少蒽环组23/220例(10%)vs 非蒽环组3/218例(1%),p<0.0001。
- 有症状的左心室收缩功能障碍两组均罕见:蒽环组2/220例(1%),非蒽环组0/218例。
- 蒽环组1例患者死于肺栓塞,可能与治疗相关。
临床怎么用
- 作者认为在早期HER2阳性乳腺癌双HER2阻断下省略蒽环类可能是首选方法。
- 作者指出需要长期随访以确认这些结果。
局限性
- 作者指出需要长期随访以确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared with a carboplatin-taxane regimen, when given in combination with the HER2-targeted agents trastuzumab and pertuzumab. METHODS: The TRAIN-2 study is an open-label, randomised, controlled, phase 3 trial being done in 37 hospitals in the Netherlands. We recruited patients aged 18 years or older with previously untreated, histologically confirmed stage II-III HER2-positive breast cancer. Patients were randomly allocated using central randomisation software (1:1 ratio) with minimisation without a random component, stratified by tumour stage, nodal stage, oestrogen receptor status, and age, to receive 5-fluorouracil (500 mg/m2), epirubicin (90 mg/m2), and cyclophosphamide (500 mg/m2) every 3 weeks for three cycles followed by paclitaxel (80 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] 6 mg/mL per min on day 1 or optionally, as per hospital preference, AUC 3 mg/mL per min on days 1 and 8) every 3 weeks for six cycles, or to receive nine cycles of paclitaxel and carboplatin at the same dose and schedule as in the anthracycline group. Patients in both study groups received trastuzumab (6 mg/kg, loading dose 8 mg/kg) and pertuzumab (420 mg, loading dose 840 mg) concurrently with all chemotherapy cycles. The primary endpoint was the proportion of patients who achieved a pathological complete response in breast and axilla (ypT0/is ypN0) in the intention-to-treat population. Safety was analysed in patients who received at least one treatment cycle according to actual treatment received. This trial is registered with ClinicalTrials.gov, number NCT01996267, and follow-up for long-term outcome is ongoing. FINDINGS: Between Dec 9, 2013, and Jan 14, 2016, 438 patients were enrolled and randomly assigned to the two treatment groups (219 patients to each group), of whom 418 were evaluable for the primary endpoint (212 in the anthracycline group and 206 in the non-anthracycline group). The median follow-up for all patients was 19 months (IQR 16-23 months). A pathological complete response was recorded in 141 (67%, 95% CI 60-73) of 212 patients in the anthracycline group and in 140 (68%, 61-74) of 206 in the non-anthracycline group (p=0·95). One patient randomly allocated to the non-anthracycline group did receive anthracyclines and was thus included in the anthracycline group for safety analyses; therefore, for the safety analyses there were 220 patients in the anthracycline group and 218 in the non-anthracycline group. Serious adverse events were reported in 61 (28%) of 220 patients in the anthracycline group and in 49 (22%) of 218 in the non-anthracycline group. The most common adverse events of any cause were grade 3 or worse neutropenia (in 131 [60%] of 220 patients in the anthracycline group vs 118 [54%] of 218 in the non-anthracycline group), grade 3 or worse diarrhoea (26 [12%] vs 37 [18%]), and grade 2 or worse peripheral neuropathy (66 [30%] vs 68 [31%]), with no substantial differences between the groups. Grade 3 or worse febrile neutropenia was more common in the anthracycline group than in the non-anthracycline group (23 [10%] vs three [1%], p<0·0001). Symptomatic left ventricular systolic dysfunction was rare in both groups (two [1%] of 220 vs 0 of 218). One patient in the anthracycline group died because of a pulmonary embolism, which was possibly treatment related. INTERPRETATION: In view of the high proportion of pathological complete responses recorded in both groups and the fact that febrile neutropenia was more frequent in the anthracycline group, omitting anthracyclines from neoadjuvant treatment regimens might be a preferred approach in the presence of dual HER2 blockade in patients with early HER2-positive breast cancer. Long-term follow-up is required to confirm these results. FUNDING: Roche Netherlands.
引用
- van Ramshorst MS, van der Voort A, van Werkhoven ED, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018. PMID: 30413379. doi:10.1016/S1470-2045(18)30570-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。